Evidence map›Paper›PMID 14738447›Full record

ArticleClinical and experimental immunology2004

Qualitative and quantitative abnormalities in splenic dendritic cell populations in NOD mice.

A C Vasquez, M Feili-Hariri, R J Tan, P A Morel

Open access · greenAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Functional specialization of islet dendritic cell subsets.Journal of immunology (Baltimore, Md. : 1950) · 2012
    Article
  14. Review
  15. Article
  16. IFN regulatory factors 4 and 8 expression in the NOD mouse.Clinical & developmental immunology · 2011
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

A C VasquezDepartment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
M Feili-Hariri
R J Tan
P A Morel
UPMC Hillman Cancer Center · US

Funding

MECHANISMS OF DENDRITIC CELL BASED TUMOR IMMUNIZATIONP01CA073743 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FINN, OLIVERA J · 1998 to 2009
$12.3M
NCI NIH HHS CA73743NCI NIH HHS P01 CA073743
6 · The paper itself

Abstract

The phenotype and function of splenic DC populations from diabetes-prone NOD mice were characterized and compared to DC from diabetes-resistant strains in the presence or absence of Flt3 ligand (FL) treatment. NOD mice were found to have significantly fewer CD8alpha+ DC than both B10.BR and C57BL/6 mice, and this defect was reversed by FL treatment. Freshly isolated CD8alpha+ and CD8alpha- DC from all three strains were found to express similar levels of costimulatory molecules and this was similar in both FL-treated and untreated animals. IL-12 p40 production was significantly lower in purified CD11c+ DC from NOD mice compared to DC from C57BL/6 or B10.BR mice. CD8alpha+ DC isolated from NOD mice produced lower levels of IL-12p40 than CD8alpha+ DC from C57CBL/6 and this was dependent on the nature of the stimulus given. In contrast both CD8alpha+ and CD8alpha- DC from FL-treated mice produced high levels of IL-12p40 following activation, but only the CD8alpha- DC produced IL-12p70. Functionally, freshly isolated CD8alpha- DC were more stimulatory than CD8alpha+ DC in a primary allogeneic mixed lymphocyte reaction. However, DC maturation resulted in increased T cell stimulatory capacity for both DC subsets, and this pattern was seen in all strains. These results demonstrate significant differences in phenotype and function of splenic NOD CD8alpha+ DC, and further suggest that FL treatment may reverse some of these abnormalities.

Indexed as

Adjuvants, ImmunologicAnimalsCD11c AntigenCD4-Positive T-LymphocytesCD8 AntigensCells, CulturedDendritic CellsDiabetes Mellitus, Type 1ImmunophenotypingInterferon-gammaInterleukin-12Interleukin-12 Subunit p40Lymphocyte Culture Test, MixedMembrane ProteinsMiceMice, Inbred C57BLAdjuvants, ImmunologicCD11c AntigenCD8 Antigensflt3 ligand proteinInterferon-gammaInterleukin-12Interleukin-12 Subunit p40Membrane ProteinsProtein SubunitsTumor Necrosis Factor-alpha

Identifiers

PMID14738447
PMCPMC1808940
OpenAlexW2005751161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.